Vaxart reports Q2 EPS (7c), consensus (9c)

Reports Q2 revenue $39.73M vs. $6.4B last year. Revenue in the second quarter was primarily from government contracts related to the BARDA contract awarded in June 2024. “We continue to make significant progress in advancing our novel, oral vaccine platform,” said Steven Lo, CEO of Vaxart (VXRT). “Prior to the stop work order, our COVID-19 trial was enrolling at a rapid pace, with approximately 5,000 participants enrolled at the time we received the order, underscoring the huge public interest in our trial. We believe the strong enrollment we achieved not only validates the demand for an alternative to current COVID-19 vaccines, but also enables us to generate meaningful data that will allow for us to assess the comparative efficacy and safety of our oral vaccine construct against an injectable mRNA comparator.”